Association of ABC and RENAL Scoring Systems With Morbidity in Partial Nephrectomy.

Background/aim: Different nephrometry scoring systems (NSSs) are used to evaluate the surgical complexity and outcomes of partial nephrectomy (PN) in patients with small renal tumors. This study aimed to assess the validity of nephrometry scoring systems towards aiding the preoperative planning of laparoscopic partial nephrectomy (PN).

Patients And Methods: Data of 77 patients who underwent partial nephrectomy at the Puerto Real University Hospital between January 2011 and December 2017 were retrospectively analyzed.

Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors.

Background/aim: The aim of the study was to evaluate the combined treatment with abiraterone acetate and prednisone (AA+P) in patients with castration-resistant prostate cancer (mCPRC), and to identify the survival prognostic factors.

Patients And Methods: Patients diagnosed with mCPRC not previously treated with chemotherapy and administered with AA+P were classified into two groups: those with lower and higher survival rates (at 30 months vs. 60 months).

Predictive Factors of Renal Function in Partial Laparoscopic Nephrectomy in Patients with a Kidney Tumor.

Background: Laparoscopic partial nephrectomy has proven to be an ideal option for tumors in initial stages, preserving part of the renal parenchyma and reducing the possible risk of glomerular filtration decrease.

Objectives: The main objective of this study is to determine the factors that can influence, to a greater extent, renal function deterioration after surgery.

Methods: This is an observational, descriptive and longitudinal study.

Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience.

Presentation of the interesting case of a patient suffering from castrate-resistant prostate cancer (CRPC) with bone metastasis, who received concomitant treatment with abiraterone acetate (AA) and radium-223. The patient experienced significant clinical improvement in his quality of life and pain relief after beginning the aforementioned treatment, without being affected by adverse toxicities. Currently, the correct selection of patients to receive radium-223 treatment is still a clinical challenge in the case of CRPC with metastasis.

[Post-hysterectomy uretero-vaginal fistula: Laparoscopic management with ureteroneocystostomy and psoas hitch.].

This paper describes our initial experience with laparoscopic ureteroneocystostomy in two patients with distal ureter lesions following gynaecological surgery (hysterectomy). Furthermore, we review the evidence on the incidence, prevention, and management of urinary tract injuries that occur during laparoscopic gynaecological surgery. METHOD: Two patients with iatrogenic lower ureteral injuries during hysterectomy leading to ureterovaginal fistula underwent laparoscopic ureteroneocystostomy with a psoas hitch.

Serum biomarkers of inflammation for diagnosis of prostate cancer in patients with nonspecific elevations of serum prostate specific antigen levels.

Background: Lactate dehydrogenase (LDH) and C-reactive protein (CRP) are biomarkers of inflammation commonly used in medicine. The aim was to evaluate the utility of serum LDH and CRP levels for diagnosis of prostate cancer (PC) in men with nonspecific elevations of serum total prostate specific antigen (PSA) levels.

Methods: The following serum biomarkers were measured in patients with PSA between 4 and 10 ng/mL: LDH, CRP and free-PSA.

[Prolonged hypogonadism after cessation of androgen deprivation therapy for prostate cancer].

Objectives: To study the levels of LH, testosterone and PSA after suspending prolonged treatment with LH-RH analogs.

Materials And Method: Hormonal evolution was studied in 29 patients from whom treatment had been withdrawn. The patients had previously been receiving treatment with LH-RH analog for more than one year, and with LH< 2 mUI/mL and testosterone < 2.